Expired activity
Please go to the PowerPak homepage and select a course.

The Pharmacist’s Role in Ending the HIV Epidemic:
Information You Need to Keep Your Practice Up to Date


James D. Scott, PharmD, FCCP, APh, AAHIVP
Associate Dean for Experiential and Professional Affairs
Western University of Health
Sciences College of Pharmacy
Pomona, California

Dr. James Scott received his Doctor of Pharmacy degree in 1994 from the University of Florida in Gainesville, Florida. He completed a one-year clinical residency in Geriatric Pharmacotherapy in 1995 at the VA Medical Center in Gainesville. In 1997, he completed a two-year fellowship in Infectious Diseases Pharmacotherapy at the University of Illinois at Chicago in Chicago, Illinois. From July 1997-April 2000, he was Director of Infection Management at the Clinical Pharmacokinetics Laboratory in Buffalo, New York. Dr. Scott joined the Western University of Health Sciences College of Pharmacy in Pomona, California in May 2000. His research, clinical practice, and academic interests are focused on HIV pharmacotherapy and adherence counseling. His research projects have included retrospective analyses evaluating the use and efficacy of HIV therapies, pharmacokinetic studies, and prospective investigator-initiated clinical trials. Dr. Scott is certified by the American Academy of HIV Medicine as an HIV Expert. He currently oversees the experiential portion of the PharmD curriculum at WesternU.

Lucas Hill, PharmD, BCACP, AAHIVP
HIV/HCV Pharmacist Specialist
UC San Diego Health System
San Diego, California

Dr. Lucas Hill completed his Doctor of Pharmacy degree at the University of Southern California in Los Angeles, California, and his pharmacy residency at UC San Diego Health (UCSD) in San Diego, California from 2011-2012. He has been a staff pharmacist at UCSD since that time, including working as an HCV pharmacist specialist from 2014-2017 and at the Owen Clinic at UCSD as a HIV/HCV pharmacist specialist since 2017. Dr. Hill is also an assistant professor at the UCSD Skaggs School of Pharmacy. His research focus is clinical research on HIV and HIV/HCV coinfection and he has been involved in research with the Owen Coinfection Clinic since 2011.


This enduring activity presents the fundamentals of human immunodeficiency virus (HIV) prevention through the implementation of preexposure prophylaxis (PrEP) services. Emphasis will be placed on taking a sexual history, screening, and risk-assessment, as well as current treatment regimens and protocols for appropriate initiation and monitoring of PrEP. It will also discuss the potential new role for expanded care by pharmacy providers, and the specific changes and opportunities for those in California in an environment of expanded pharmacy scope of practice. The program will equip pharmacists with the most recent clinical and pharmacologic information based on the guidelines of the American Society of Health Systems Pharmacists (ASHP) and the US Public Health Service clinical practice guidelines. The activity will show the important roles that pharmacists play as trusted members of the HIV-prevention team, as links to care, and as potential PrEP providers.


This activity is intended for clinical and community pharmacists involved in the care of patients at risk for HIV infection.


Upon completion of this activity, participants should be better able to:

  • Demonstrate understanding of the epidemiology, burden, and stigma surrounding HIV risk and transmission
  • Utilize practice guidelines to screen for HIV risk and determine clinical eligibility for PrEP
  • Compare prescribing options for PrEP in terms of efficacy, safety, and dosing regimens


Joint Accreditation StatementIn support of improving patient care, this enduring activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.


acpePostgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – JA4008162-9999-20-2211-H01-P)

This is a knowledge-based activity.


PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

Lucas Hill, PharmD, BCACP, AAHIVP Nothing to disclose
James D. Scott, PharmD, FCCP, APh, AAHIVP Nothing to disclose


The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.


In order to receive credit for this activity, the participant must receive a minimum score of 80% on the posttest and complete the evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

CPE Questions – PIM Contact Information

For information about the accreditation of this program, please contact PIM via e-mail at inquiries@pimed.com or by visiting www.pimed.com.

Integritas Contact Information

For all other questions regarding this webinar, please contact Integritas via email at info@exchangecme.com.

We would like to thank the American Academy of HIV Medicine (AAHIVM) for their collaboration and support.

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

This activity is supported by an independent educational grant from Gilead Sciences, Inc.